Shandong Sito Bio-technology Co., Ltd. Class A

Shandong Sito Bio-technology Co., Ltd. Class A

SSZSE:300583
10.65
CNY
-0.22
(-2.02%)
0.16EPS
87.90P/E
2.60BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.66
4.07
5.22
4.42
4.7
6.15
5.68
5.33
7.06
7.5
7.02
5.14
5.42
6.09
Basic EPS, GAAP
0.24
1.29
1.46
0.79
0.55
0.74
0.32
-1.05
0.21
0.24
0.25
-0.47
-0.39
0.16
Free Cash Flow per Basic Share
-0.13
-0.43
-0.34
-0.36
-0.39
-4.17
-0.9
0.07
-0.95
0.01
-1.02
0.68
0.42
- -
Dividend per Share
0.03
0.05
0.09
0.11
0.09
0.15
0.28
0.22
0.14
0.25
0.18
0.6
0.15
0.13
Book Value per Share
0.77
2.27
3.74
3.4
9.78
11.04
10.63
9.56
9.81
10.05
10.61
9.69
9.29
9.3
Tangible Book Value per Share
0.68
1.89
3.22
3.02
9.36
10.47
9.37
8.57
8.76
9.04
9.55
8.7
8.33
8.36
Basic Weighted Avg Shares
171
128
128
128
167
171
170
171
170
175
182
189
188
187
Sales/Revenue/Turnover
284
521
668
568
786
1,052
966
913
1,203
1,312
1,280
971
1,017
1,138
Operating Margin (%)
22.81
39.03
35.48
22.89
11.8
13.8
8.96
-8.71
8.07
6.38
6.62
-0.79
0.34
8.31
Depreciation Expense
3
17
34
44
60
68
83
143
135
163
174
175
168
- -
Net Income, GAAP
42
166
187
101
92
126
55
-180
36
42
46
-89
-73
29
Effective Tax Rate (%)
25.77
14.58
14.72
16.84
16.96
15.19
24.2
- -
34.08
11.37
9.22
- -
- -
38.5
Profit Margin (%)
14.66
31.81
27.99
17.81
11.71
11.98
5.73
-19.69
3.01
3.2
3.56
-9.15
-7.19
2.56
Working Capital
69
48
190
204
1,029
943
564
199
25
55
411
261
279
248
LT Debt
45
100
140
158
- -
85
146
196
164
124
116
80
135
116
Total Equity
99
291
507
603
1,707
1,961
1,887
1,691
1,732
1,771
2,065
1,884
1,797
1,800
Return on Invested Capital (%)
38.52
54.56
32.57
12.3
6.37
5.78
1.98
- -
1.55
1.79
1.11
- -
- -
1.15
Return on Capital (%)
44.56
57.66
35.19
15.07
7.76
6.55
3.3
- -
2.38
3.04
2.88
- -
- -
1.76
Return on Common Equity (%)
63.31
85.08
48.63
19.12
8.11
7.01
2.96
-10.35
2.18
2.47
2.44
-4.61
-4.06
1.64

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
650
587
628
LT Borrowings
126
137
116
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
190
190
190
Market Capitalization
2,682
2,130
2,599

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,251
1,268
1,292
Cash, Cash Equivalents & STI
237
261
234
Accounts Receivable, Net
343
309
272
Inventories
396
458
544
Total Current Liabilities
985
1,005
1,045
Payables & Accruals
- -
- -
- -
ST Debt
650
587
628
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.07%
1.57%
-4.64%
Free Cash Flow
-1,225.54%
-2,624.18%
-38.82%
Net Income, GAAP
-90.7%
-81.56%
-17.6%
Sales/Revenue/Turnover
6.25%
3.79%
4.77%
Total Cash Common Dividend
36.51%
38.63%
-75.4%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
244
322
198
206
971
2025
260
248
- -
268
1,017
2026
328
285
257
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.05
0.01
-0.55
-0.47
2025
-0.15
-0.13
- -
-0.02
-0.39
2026
0.02
0.14
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.03
0.48
0.03
0.6
2025
0.04
0.04
- -
0.03
0.15
2026
0.04
0.04
0.03
- -
- -

Company Description

CEO
Qi Mi
Full Time Employees
990
Sector
Health technology
Industry
Pharmaceuticals: major
Address
South section of East Outer Ring Road, Heze SD China 274100
IPO Date
Jan 6, 2017
Business
Shandong Sito Bio-technology Co., Ltd. researches, develops, produces, and sells steroid biomedicine intermediates and raw materials for pharmaceutical companies using genetic engineering and microbial transformation technologies. The company offers core products including androstenedione (4-AD), 1,4-androstadiene-3,17-dione (ADD), 9-hydroxyandrostenedione (9OH-AD), 17α-hydroxyprogesterone, 17α-acetoxyprogesterone, progesterone intermediate (2DM), tetraene acetate (3TR), medroxyprogesterone (8DM), anecort acetate, tylvalosin tartrate, bisnoralcohol, norandrostenedione, estra-4,9-diene-3,17-dione, androsta-1,4-diene-3,17-dione, 16β and 16α methyl epoxide, and hexahydro-3α-methyl derivatives. Founded in 2002 and headquartered in Heze City, Shandong Province, China, the company operates primarily in the biopharmaceutical industry, serving global pharmaceutical manufacturers with production facilities covering 200,000 square meters and a dedicated R&D team. Shandong Sito maintains recognition as a national high-tech enterprise, Shandong Engineering Laboratory, and a leading enterprise in Shandong's top industrial clusters, with stable partnerships alongside gene sequencing firms and research institutes including Wuhan University and the Chinese Academy of Sciences. The company listed on the Shenzhen Stock Exchange in 2017 (ticker: 300583.SZ) and completed the acquisition of an 80% stake in Lisapharma S.p.A. in recent years to expand its operations.